文献速递血脂与心血管预防冠心病肺血管病与心包/心肌炎

PCSK9抑制剂的未来演变

The Evolving Future of PCSK9 Inhibitors.
PubMed 文献 · J Am Coll Cardiol · 2018-07-09

本文综述PCSK9抑制剂的研究进展:人类单克隆抗体在高危患者中降低LDL-C达55%至72%,临床试验显示可减少动脉粥样硬化性心血管疾病事件,尤其近期急性冠脉综合征、多支冠状动脉病变或外周动脉疾病患者;LDL-C降至<25 mg/dl伴随更低事件率,支持LDL-C可能无下限;安全性良好;推荐用于最大耐受口服治疗下LDL-C≥70 mg/dl的高危患者。

要点

  • PCSK9单克隆抗体在高危患者中降低LDL-C 55%–72%。
  • 临床试验显示PCSK9抑制剂减少ASCVD事件,尤其近期ACS、多支冠脉病变或PAD患者。
  • LDL-C降至<25 mg/dl伴随更低事件率,支持LDL-C无下限概念,安全性良好。

核心结论

  • PCSK9抑制剂可显著降低高危患者LDL-C并减少动脉粥样硬化性心血管疾病事件,安全性良好,支持LDL-C无下限概念。

研究设计与样本

  • 综述性文章,总结PCSK9基因变异机制、人类单克隆抗体临床试验证据及推荐。

主要发现

  • 人类单克隆抗体靶向PCSK9在不同高危患者组中降低LDL-C 55%至72%。
  • PCSK9抑制剂临床试验显示减少动脉粥样硬化性心血管疾病事件,尤其近期急性冠脉综合征、多支冠状动脉病变或外周动脉疾病患者。
  • 常见LDL-C大幅降至<25 mg/dl伴随更低动脉粥样硬化性心血管疾病事件率。
  • 全人源PCSK9单克隆抗体强化降LDL-C的安全性特征非常良好。

关键数值与推荐

  • 基于临床试验证据,推荐最大耐受口服治疗(包括他汀和/或依折麦布)下LDL-C≥70 mg/dl的高危患者使用PCSK9抑制剂降LDL。

临床怎么用

  • 对最大耐受口服降脂治疗下LDL-C仍≥70 mg/dl的高危患者,可考虑加用PCSK9抑制剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Variants in proprotein convertase subtilisin/kexin type 9 (PCSK9) provide insights into mechanisms regulating low-density lipoprotein (LDL) levels. Human monoclonal antibodies that target PCSK9 lower LDL cholesterol (LDL-C) levels by 55% to 72% in different high-risk patient groups. Clinical trials with PCSK9 inhibitors have demonstrated reductions in atherosclerotic cardiovascular disease events, particularly in patients with recent acute coronary syndrome, multivessel coronary artery disease, or peripheral arterial disease. Commonly observed profound reductions in LDL-C to levels <25 mg/dl have been accompanied by even lower rates of atherosclerotic cardiovascular disease events, thus supporting the concept that there may be no lower limit for LDL-C. Aggressive LDL-C lowering with fully human PCSK9 monoclonal antibodies has been accompanied by a safety profile that has been very favorable. On the basis of clinical trial evidence, LDL lowering with PCSK9 inhibitors is recommended for high-risk patients with LDL-C levels ≥70 mg/dl on maximally tolerated oral therapies including statins and/or ezetimibe.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Rosenson RS, Hegele RA, Fazio S, et al. The Evolving Future of PCSK9 Inhibitors. J Am Coll Cardiol. 2018. PMID: 30012326. doi:10.1016/j.jacc.2018.04.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。